AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
Status:
Not yet recruiting
Trial end date:
2027-04-03
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety, side effects, and best dose of a new intervention,
AU409, in treating patients with primary liver cancers that may have spread from where it
first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or
advanced solid tumors that have spread to the liver (liver metastatic disease). AU409 may
stop cancer from growing and spreading. This trial may help researchers determine if AU409 is
safe and effective in treating patients with liver cancers and solid tumors with liver
metastatic disease.